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Abstract 
Oxidative stress plays a major role in the pathogenesis of both types of diabetes mellitus and 
cardiovascular diseases including hypertension. The low levels of antioxidants accompanied 
by raised levels of markers of free radical damage play a major role in delaying wound 
healing. Ultra-low microcurrent presumably has an antioxidant effect, and it was shown to 
accelerate wound healing. The purpose of the study is to investigate the efficacy of ultra-low 
microcurrent delivered by the Electro Pressure Regeneration Therapy (EPRT) device (EPRT 
Technologies-USA, Simi Valley, CA) in the management of diabetes, hypertension and 
chronic wounds. The EPRT device is an electrical device that sends a pulsating stream of 
electrons in a relatively low concentration throughout the body. The device is noninvasive 
and delivers electrical currents that mimic the endogenous electric energy of the human 
body. It is a rechargeable battery-operated device that delivers a direct current (maximum of 
3 milliAmperes) of one polarity for 11.5 minutes, which then switched to the opposite po-
larity for another 11.5 minutes. The resulting cycle time is approximately 23min or 0.000732 
Hz and delivers a square wave bipolar current with a voltage ranging from 5V up to a 
maximum of 40 V. The device produces a current range of 3 mA down to 100 nA. Twelve 
patients with long standing diabetes, hypertension and unhealed wounds were treated with 
EPRT. The patients were treated approximately for 3.5 h/day/5 days a week. Assessment of 
ulcer was based on scale used by National Pressure Ulcer Advisory Panel Consensus De-
velopment Conference. Patients were followed-up with daily measurement of blood pres-
sure and blood glucose level, and their requirement for medications was recorded. Treat-
ment continued from 2-4 months according to their response. Results showed that diabetes 
mellitus and hypertension were well controlled after using this device, and their wounds 
were markedly healed (30-100%). The patients either reduced their medication or com-
pletely stopped after the course of treatment. No side effects were reported. The mecha-
nism of action was discussed. 
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Introduction 
Diabetes mellitus and cardiovascular diseases 
are challenging medical and social problems. Patients 
with diabetes mellitus are at a higher risk of devel-
oping vascular dysfunction and hypertension. The 
real etiology of these diseases is not well understood. 
However, cumulative evidence suggests that oxida-
tive stress may play a key role in the development of 
diseases. It has been found that oxidative stress is 
associated with several cardiovascular diseases,  in-
cluding atherosclerosis, hypertension, heart failure, 
stroke, and diabetes, and plays a fundamental role in 
endothelial dysfunction associated with these diseases 
(1-6). Further, oxidative stress plays a major role in the 
pathogenesis of both types of diabetes mellitus. High 
levels of free radicals and the decline of antioxidant 
defense mechanisms lead to d a m a g e  o f  c e l l u l a r  o r -
ganelles and enzymes, increased lipid peroxidation, 
and development of insulin resistance (7). The vascu-
lar and systemic complications in diabetes are associ-
ated with hyperglycemia-induced overproduction of 
reactive oxygen species (8,9). Other studies showed 
that overproduction of reactive oxygen and nitrogen 
species, lowered antioxidant defense and alterations 
of enzymatic pathways in humans with poorly con-
trolled diabetes mellitus can contribute to endothelial, 
vascular and neurovascular dysfunction (10). Insulin 
resistance is associated with reduced intracellular an-
tioxidant defense, and therefore diabetic patients may 
have a defective intracellular antioxidant response 
that causes diabetic complications (11-13). 
The combination of the low levels of antioxi-
dants and raised levels of free radical play a major 
role in delaying wound healing in aged rate and dia-
betic rats (14). It has been found that chronic leg ulcers 
contain localized oxidative stress (15). The recent 
finding revealed that insulin resistance is associated in 
humans with reduced intracellular antioxidant (11). 
Interestingly, antioxidants improve insulin sensitivity 
and help in wound healing (16,17). 
Along with others, the investigators have used 
microcurrent for treatment of chronic wounds and 
ulcers (18-20). In an earlier work, The Electro Pressure 
Regeneration Therapy (EPRT) device which produces 
a current range of 3 mA down to 100 nA, was used for 
treatment of chronic wounds and ulcers associated 
with chronic disease (21). The device used in the ex-
periment was supposed to deliver electrons to tissues 
and then saturated free radicals with required elec-
trons. The actual tissue regeneration, along with con-
comitant improvement noted in the general condition 
of the patient, points to a highly potent antioxidant 
effect on local tissues, as well as on tissues in general. 
This reduces free radicals and might facilitate tissue 
repair. This device is used as a model to deliver elec-
trons to the body, including mitochondria and pre-
sumably working as an antioxidatant device. It was 
thought reasonable to use on patients with diabetes 
mellitus, hypertension and chronic wounds, to test 
whether delivering electrons to the body might help 
eliminate underlying oxidative stress, stabilize mito-
chondria and prevent further formation of excess free 
radicals. 
Patients and methods 
Electro Pressure Regeneration Therapy Device  
The EPRT device is an electrical device that 
sends a pulsating stream of electrons in a relatively 
low concentration throughout the body. The device is 
noninvasive and delivers electrical currents that 
mimic the endogenous electric energy of the human 
body. It is a rechargeable battery-operated device that 
delivers a direct current (maximum of 3 milliAm-
peres) of one polarity for 11.5 minutes, which then 
switched to the opposite polarity for another 11.5 
minutes. The device was designed to switch the di-
rection of current flow halfway through the cycle. The 
resulting cycle time is approximately 23min or 
0.000732 Hz and delivers a square wave bipolar cur-
rent with a voltage ranging from 5V up to a maximum 
of 40 V. The device produces a current range of 3 mA 
down to 100 nA. Electrodes are applied in 2 layers, 
and tap water is used as the conducting medium. The 
wraps cover a large surface area, thus reducing resis-
tance and allowing an optimum number of electrons 
to flow freely into tissues. 
Patients and treatments 
Case 1: The first patient was a 74 year old female 
with poorly controlled non-insulin- dependent dia-
betes, hypertension, and hypercholesterolemia. She 
was seen with vomiting, diarrhea and gangrene of 
second toe on left foot. Two weeks prior to admission, 
the patient had sustained fall in the bathroom result-
ing in a left ankle fracture with vomiting and diarrhea 
for seven days. The patient was treated with met-
formin and augmentin. Upon examination, the patient 
was afebrile with stable vital signs, and femoral 
pulses were present bilaterally. Popliteal and pedal 
pulses were absent bilaterally with poor capillary re-
fill. The left foot was red and inflamed up to and in-
cluding the medial malleolus. The lateral aspect of the 
great toe and second toe turned black. Laboratory 
investigation revealed elevated blood glucose (17.9 
mmol/L) and hyponatremia (Na+ 128 mEg/L). The Int. J. Med. Sci. 2010, 7 
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patient underwent a medial forefoot amputation as 
part of her management. Within 28 days after surgery, 
the 4th and 5th toes become discolored, dusky purple 
and black. The patient also developed a large blood 
blister over her heel. Vascular opinion was for a below 
knee amputation. The patient was self- discharged 
against medical advice. The patient was started on 
treatment by Electro Pressure Regeneration Therapy 
device (EPRT) while she was in hospital. She contin-
ued daily treatments on the EPRT device at home, 
along with a diabetic diet. The left foot continued to 
improve and heal, and her remaining gangrenous toes 
eventually fell off. Her blood pressure at admission 
was 166/53 with use of Lisinopril, which was 
dropped and eventually ceased as her BP continued to 
drop; 146/68, 129/64, 144/67 in second, third and 
fourth weeks after treatment, and to 128/66 during 6th 
to 8th weeks post-treatment while the patient was on 
no medication. Her blood sugar was improved and 
HbA1c was dropped from 9.8 before treatment to 7.6, 
6.5, 5.9 and 5.5 during 9 months after commencement 
of treatment. The patient eventually stopped diabetic 
and hypertensive medications. To date her HbA1c 
remains below 6 on diet alone. 
Case 2: The second patient was a 65 year old 
male with a long history of non insulin dependent 
diabetes and hypertension. Diabetic neuropathy had 
affected his feet and he could not feel the shoe rub-
bing. A small superficial ulcer developed on his 5th toe 
which became infected and subsequently, the 5th toe 
was amputated. His condition rapidly deteriorated 
and he developed necrotizing fasciitis and osteomye-
litis. Consequently, he had surgery removing tendons, 
skin and the capsular linings of joints from his right 
foot. The patient was discharged after ten weeks in 
hospital with a large, infected, open wound requiring 
community nurses to do wound management. The 
patient was treated by the Electro Pressure Regenera-
tion Therapy device; the wound was healed com-
pletely without further management and the diabetes 
was well controlled. HbA1c dropped from 7.3 to 6.6 
after treatment. His blood pressure was 202/99 before 
the treatment, which was dropped to 155/73 after two 
weeks. His blood pressure continued within normal 
range with the use of the Electro Pressure Regenera-
tion Therapy device 2-3 times weekly. 
Case 3: A 70 year old female was diagnosed with 
hypertension, epilepsy osteoarthritis and rheumatoid 
arthritis. Her blood pressure was 147/84 which was 
dropped to 138/72 three weeks after the treatment 
with the Electro Pressure Regeneration Therapy de-
vice. She continued using the EPRT device twice 
weekly and her blood pressure was under control 
without the use of antihypertensive medications. 
Case 4: A 77 year old female with hypertension, 
hypercholesterolemia, hypothyroidism, and type 2 
diabetes (NIDDM) was treated with the Electro Pres-
sure Regeneration Therapy device. Her blood pres-
sure before treatment was 158/81 which was dropped 
to 125/65 after 1 week. Her blood pressure continued 
to be normal with use of the EPRT device despite 
discontinuation of antihypertensive medications. 
HbA1c was 7.8 before treatment which decreased to 
6.9 and continued to be low during one year fol-
low-up. 
Case 5: A 67 year old female with hypertension 
and osteoarthritis was treated with the Electro Pres-
sure Regeneration Therapy device. Her blood pres-
sure was 157/91 which dropped to 149/86 after 3 
weeks. 
Case 6: A 70 year old female with hypertension, 
fibromyalgia, hepatitis, hypercholesterolemia, tuber-
culosis and a stroke was treated with the Electro 
Pressure Regeneration Therapy device for her hyper-
tension. Her blood pressure was 134/84 before treat-
ment which was dropped to 117/73 within 4 weeks 
after treatment despite discontinuation of her anti-
hypertensive medication.  
Case 7: A 75 year old female with hypertension 
and benign postural vertigo was treated with the 
Electro Pressure Regeneration Therapy device. Her 
blood pressure was 157/86 before treatment, which 
was dropped to 138/76 and continued within normal 
limits while receiving one treatment per week. 
Case 8: A 53 year old female with type 1 diabetes 
(IDDM) from the age of 12, suffered renal failure as a 
result of her diabetes and underwent a kidney and 
pancreatic transplant in 1994. She also has hypercho-
lesterolemia, left ventricular failure, renal failure and 
a history of a coronary artery bypass graft. She then 
started treatment with the Electro Pressure Regenera-
tion Therapy device. While she is not considered to 
currently have diabetes her HbA1c dropped over the 
time period she was receiving treatments from 5.4 to 
5.1. This was matched by her Blood Sugar Level (BSL) 
which also stabilized while she was receiving treat-
ment over this period of time. 
Case 9: A 32 year old female with type 1 diabetes 
(IDDM) and no other concurrent health problems was 
treated with the Electro Pressure Regeneration Ther-
apy device. She received 8 treatments over a two week 
period. HbA1c before treatment was 8.1 and was 
dropped to 7.1 after treatment. Her insulin require-
ment was also reduced. 
Case 10: A 59 year old female with type 2 diabe-
tes (NIDDM), hypertension, fibromyalgia, chronic 
active hepatitis, and Bowens disease was treated with 
the Electro Pressure Regeneration Therapy device. Int. J. Med. Sci. 2010, 7 
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Her blood sugar was normalized and HbA1c dropped 
from 7.2 to 6.3 after the treatment. Her HbA1c showed 
a slight increase to 6.4 within three months after 
therapy was discontinued. 
Case 11: A 70 year old female with type 2 diabe-
tes (NIDDM), osteoarthritis, chronic pain and multi-
ple operations was treated with the Electro Pressure 
Regeneration Therapy device. Her average Blood 
Sugar Level (BSL) before treatment was 9.8, and 
dropped to 7.4 and 7.1 after three and six months of 
treatment. She was treated twice weekly with the 
EPRT device. 
Case 12: A 68 year old male with type 2 diabetes 
(NIDDM), hypertension, stroke, chronic pain and po-
lio was treated with the Electro Pressure Regeneration 
Therapy device. HbA1c before treatment was 7.8, 
which was dropped to 6.6 during treatment. He was 
treated three times per week most weeks during a six 
month period. Upon discontinuation of therapy 
HbA1c increased to 7.8. 
Discussion 
The results of this preliminary trial showed that 
ultra-low microcurrent has apparent therapeutic ef-
fects on diabetes, hypertension and wound healing. 
Presumably, one of mechanisms of action is its anti-
oxidant activity. The action of EPRT is to produce 
electrical pressure rather than an electrical jolt as 
produced by a Transcutaneous Electrical Nerve 
Stimulator. Whereas Transcutaneous Electrical Nerve 
Stimulator device can produce a current varying from 
1uA to 100 mA, the EPRT ranges from 100 nA to 3 
mA. Moreover, Transcutaneous Electrical Nerve 
Stimulator frequency range is from 0.5 to 40,000 Hz 
with a range of cycle times from 2 seconds to 0.025 
milliseconds. The EPRT has a frequency of approxi-
mately 0.000732Hz which gives a frequency time of 
22.77 minutes. Namely, Transcutaneous Electrical 
Nerve Stimulator with power of 10 mA and a fre-
quency of 1 Hz is delivering approximately 6x10 (14) 
electrons per cycle. As the cycle is 1 second all these 
electrons were delivered in that period as a jolt. The 
EPRT at a setting of 100 nA is delivering 8.129x10 (14) 
per cycle. But as this amount is being delivered over a 
23 minute period (at rate of 6x10 (11) electrons per 
second) this behaves as a pressure instead of a jolt. 
This steady stream of electrons is what makes the 
EPRT a super antioxidant and not only does this cor-
rect malalignments in the cells electrical system but it 
also eliminates free radicals and then stimulates the 
mitochondria to produce ATP. 
Microcurrent has been successfully used to en-
hance soft tissue healing and to treat fracture nonun-
ion (22,23). Microcurrent relieves myocontracture and 
can enhance conventional rehabilitation programs for 
children with cerebral palsy (24). Studies from the 
1980s suggest that microcurrent therapy is effective at 
relieving the side effects of radiation therapy (25). The 
investigators have found that direct electrical therapy 
was effective in healing gum abscess and accelerated 
wound healing (20). Substances that increase electrical 
field, such as prostaglandin E2, enhance the wound 
healing rate and increase cell division (26-28). Elec-
trical fields stimulate secretion of growth factor (28). 
Low mA current stimulates adenosine triphosphate 
production (26). It is discovered in another study that 
microcurrent stimulates dermal fibroblasts and U937 
cells to secrete transforming growth factor-β1, a major 
regulator of cell-mediated inflammation and tissue 
regeneration (29). 
Insulin resistance plays a major role in the de-
velopment of  several metabolic abnormalities and 
diseases such as type 2 diabetes mellitus, obesity and 
the metabolic syndrome (30). In these conditions there 
is an elevation of both glucose and free fatty acid lev-
els in the blood and an increase in oxidative stress 
(30,31). The high degree of oxidative stress might have 
an important role in decreasing insulin responsive-
ness (31-33). 
Many studies have suggested that ß-cell dys-
function  results from prolonged exposure to high 
glucose and elevated free fatty levels (33). High glu-
cose concentrations induce mitochondrial  reactive 
oxygen species, which suppresses the first phase of 
glucose-induced insulin secretion (34). ß-cells are par-
ticularly sensitive to reactive oxygen species because 
they are low in antioxidant enzymes such as catalase, 
glutathione peroxidase,  and superoxide dismutase 
(35). Therefore, the oxidative  stress might damage 
mitochondria and markedly blunt insulin secretion 
(34). Recent studies suggested that ß-cell lipotoxicity is 
enhanced by concurrent hyperglycemia and that oxi-
dative stress may be the mediator (36,37). An increase 
in insulin, free fatty acid, and/or glucose levels can 
increase reactive oxygen species production and oxi-
dative stress, as well as activate stress-sensitive 
pathways (33). Many studies show that postprandial 
hyperglycemia  is associated with oxidative stress 
generation (38). Repeated exposure to hyperglycemia 
and increased levels of free fatty acid can lead to ß-cell 
dysfunction that may become irreversible over time. It 
has been suggested that oxidative stress might be the 
mediator of damage to cellular components of insulin 
production (33,39). 
A major source of cellular reactive oxygen spe-
cies is mitochondria, whose dysfunction contributes to 
pathological conditions such as vascular complica-
tions  of diabetes, neurodegenerative diseases and Int. J. Med. Sci. 2010, 7 
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cellular senescence (40-45). Source of reactive oxygen 
species in insulin secreting pancreatic β-cells and cells 
that are targets for insulin action is considered to be 
the mitochondrial electron transport  chain. Hyper-
glycemia and lipotoxicity in obesity and related dis-
orders are associated with mitochondrial dysfunction 
and oxidative stress (46,47). Oxidative stress–induced 
activation of NF-κB signaling might be associated 
with the pathogenesis of insulin resistance and type 2 
diabetes (48-51). In obesity and type 2 diabetes it has 
been reported that antioxidants and IKK-B inhibitors 
protect against insulin resistance (52,53). 
Data show that increased lipid peroxidation in 
NIDDM has implications for vascular disease in dia-
betes (54). Oxidative stress plays an important role in 
the pathogenesis of cardiovascular diseases including 
hypertension (55). Clinical studies suggest the occur-
rence of increased reactive oxygen species production 
in humans with essential hypertension (56,57). Oxi-
dative stress is considered to be a unifying mechanism 
for hypertension and atherosclerosis (58,59). 
Oxygen free radicals play a major role in the 
failure of ischemic wound healing, while antioxidants 
partly improve the healing in ischemic skin wounds 
(60). Oxygen free radicals mediate the inhibition of 
wound healing following ischemia-reperfusion and 
sepsis (61). It seems that diabetes mellitus, cardio-
vascular disease, such as hypertension, and delayed 
wound healing have a common important basic 
pathogenesis, which is related to imbalance between 
free radical production and removal. The use of ul-
tra-low microcurrent might help in stabilizing mito-
chondria, working as antioxidants and therefore, en-
hancing normal function of β-cells and vascular tis-
sue. Several clinical trials have demonstrated that 
treatment with vitamin E, vitamin C, or glutathione 
improves insulin sensitivity in insulin-resistant indi-
viduals (16,62). The acute effects of hyperglyce-
mia-dependent  endothelial cells dysfunction  are 
counterbalanced by antioxidants (63-65). But clinical 
trials with antioxidants, in particular with vitamin E, 
have failed to show  any beneficial effect (66). How-
ever, antioxidant therapy with vitamin E or other an-
tioxidants is limited to scavenging  already formed 
oxidants and may be considered symptomatic instead 
of a causal treatment for oxidative stress (67). Inter-
ruption of the overproduction of superoxide by the 
mitochondrial  electron transport chain would nor-
malize the pathways involved in the development of 
the oxidative stress (68). 
If our findings are proven by further studies in-
volving a larger number of patients, ultra-low mi-
crocurrent therapy might change the concept of 
management of chronic disease. Conclusively, oxida-
tive stress and oxidative damage to tissues are com-
mon pathology of chronic diseases, and using anti-
oxidants, such as the EPRT device used in this ex-
periment, might change the concept of management 
of chronic diseases. 
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